Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 5, 2018Bioscience ReportsOpen Access

Treatment with AS-IV improved heart function and structure, increased expression of PPARα, MCAD, and MCPT1, and improved FFA utilization in comparison with the CHF group.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does Astragaloside IV improve ventricular remodeling and energy metabolism in a rat model of chronic heart failure?

Population

Sprague-Dawley rats with chronic heart failure (CHF model), n=100 (5 groups, n=20 per group)

Comparison

Astragaloside IV at low-dose or high-dose for 8… vs CHF control group, sham control group, and CHF +…

Design

Preclinical

Follow-up

8 weeks

Authors

BTBin TangXinjiang Medical UniversityJZJinguo ZhangFanjingshan National Nature ReserveHTHong-yong TanAffiliated Hospital of Jining Medical University

Discussion

Loading...

Member takes

Overview

Does not support clinical use; leaves open whether AS-IV benefits translate beyond rat models.

Structured PICO

Does Astragaloside IV improve ventricular remodeling and energy metabolism in a rat model of chronic heart failure?

P
Population
Sprague-Dawley rats with chronic heart failure (CHF model), n=100 (5 groups, n=20 per group)
I
Intervention
Astragaloside IV (AS-IV) at low-dose (30 mg/kg/day) or high-dose (60 mg/kg/day) for 8 weeks
C
Comparator
CHF control group, sham control group, and CHF + benazepril hydrochloride group
O
Outcome
Cardiac structure and functional parameters, morphological changes, and expression of PPARα, MCAD, and MCPT1 at 8 weekssurrogate

Astragaloside IV demonstrates therapeutic potential in chronic heart failure by inhibiting ventricular remodeling and improving fatty acid utilization in a rat model.

Cite This Study

Tang et al. (2018) studied this question.

synapsesocial.com/papers/6a1e9b0c8fda1017a847df59https://doi.org/10.1042/bsr20171036
View Full Paper
Ask AI
Bookmark
Share